Mattia Galli/LinkedIn
Nov 2, 2025, 05:36
Mattia Galli on Use of Genetic Testing to Guide the Choice of Antiplatelet Drugs
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Growing interest in Rome in the use of genetic testing to guide the choice of antiplatelet drugs.
Is the time finally ripe for cardiology to move towards precision drug therapy?
A wonderful meeting and stimulating discussion with colleagues from one of Rome’s most important hospitals, in a session moderated by some of the “teachers” I had the pleasure of meeting during my specialization course.
Francesco Burzotta, Gaetano Antonio Lanza.”
Stay updated with Hemostasis Today.
-
May 7, 2026, 07:48Could Albuminuria Be an Overlooked Marker of Thrombotic Risk? – RPTH Journal
-
May 7, 2026, 07:37Matías J Alet: On the Implementation of Tenecteplase for Acute Ischemic Stroke at ESOC 2026
-
May 7, 2026, 07:21Britta Diebel: Reflections on Healthcare Impact from the PPTA IPPC Congress
-
May 7, 2026, 07:02Ana Cláudia de Souza: NeuroLeadership, Management and Behavioural Insights in Stroke Care from ESOC 2026
-
May 7, 2026, 07:00Maxime Dely: Just 60 Minutes of Our Time to Help a Patient We Will Never Meet
-
May 7, 2026, 06:37Anagha Kulkarni: Insights and A Prize from ISBMT Annual Conference 2026
-
May 7, 2026, 06:37Neelmani Singh: Why Iron Deficiency Is a Brain Health Issue
-
May 7, 2026, 06:25Vivek Sinha: The Science Behind a CBC Test
-
May 7, 2026, 06:17Emily Brown: Honor to Represent Hemophilia of Georgia at 2026 World Federation of Hemophilia Congress